FAQs
What does Arcturus Therapeutics do?
Arcturus Therapeutics is a messenger RNA (mRNA) medicines company focused on the development of liver and respiratory rare disease therapeutics with key platform technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® self-amplifying mRNA technology (sa-mRNA), (iii) design and optimization of mRNA drug substance and (iv) proprietary manufacturing processes.
Where is Arcturus Therapeutics located?
Arcturus Therapeutics is headquartered in San Diego, California, a leading U.S. biotechnology hub for RNA, including mRNA, medicine development.
When was Arcturus Therapeutics founded?
Arcturus Therapeutics was founded in 2013.
Who leads Arcturus Therapeutics?
Arcturus Therapeutics is led by founders Joseph Payne, President, and Chief Executive Officer, and Pad Chivukula, PhD, Chief Scientific Officer and Chief Operating Officer, supported by an experienced leadership team and board of directors with deep expertise in biotechnology, RNA science, and drug development.
Is Arcturus Therapeutics a public company?
Yes. Arcturus Therapeutics is a publicly traded company listed on NASDAQ stock exchange under the ticker symbol ARCT. Investor information, stock performance, and financial reports are available through the company’s Investor Relations website: https://ir.arcturusrx.com/.
What diseases does Arcturus Therapeutics focus on?
Arcturus focuses on therapeutics for rare genetic disorders and liver diseases, including ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF). Arcturus developed KOSTAIVE, the world’s first approved self-amplifying RNA (sa-mRNA) COVID vaccine, and has an ongoing global collaboration with CSL Seqirus for KOSTAIVE and vaccines to other infectious diseases.
What makes Arcturus Therapeutics unique?
Arcturus Therapeutics is an mRNA medicines company focused on the development of liver and respiratory rare disease therapeutics. The Company leverages its proprietary STARR® self-amplifying mRNA (sa-mRNA) technology and LUNAR® lipid delivery system to create potent, durable vaccines with lower dose requirements.
Arcturus achieved a major milestone with KOSTAIVE®, the first self-amplifying mRNA COVID-19 vaccine approved worldwide. Its pipeline includes programs in cystic fibrosis (ARCT-032, Phase 2), OTC deficiency (ARCT-810, Phase 2).
The Company’s platform supports multiple modalities, including mRNA, sa-mRNA, siRNA, circular RNA, antisense RNA, DNA, and gene editing. By integrating proprietary discovery, manufacturing, and delivery capabilities, Arcturus maintains control over both drug substance and drug product, enabling scalability and cost efficiency.
Through collaborations with partners such as CSL Seqirus, BARDA, and ARCALIS (Japan Joint Venture), and supported by a broad intellectual property portfolio, Arcturus is advancing a new generation of RNA-based medicines across rare diseases and vaccines.